HGH (Somatropin): The Complete Guide

Overview

Human growth hormone (HGH) is the most abundant hormone produced by the anterior pituitary gland. Endogenous GH is secreted in pulsatile bursts -- primarily during deep sleep -- and plays a central role in linear growth during childhood, body composition regulation, metabolic homeostasis, and tissue repair throughout life. Natural GH production peaks during adolescence and declines progressively with age, a phenomenon termed the "somatopause" (Bartke, 2019).

Recombinant human growth hormone (rhGH), marketed as somatropin, was first approved by the FDA in 1985 after replacing the earlier pituitary-derived growth hormone (which was withdrawn due to contamination with Creutzfeldt-Jakob disease prions). Somatropin is produced using recombinant DNA technology and is structurally identical to the 191-amino acid, single-chain polypeptide produced by somatotroph cells in the anterior pituitary (Molitch et al., 2011).

Since its approval, somatropin has become one of the most commercially successful biopharmaceutical products, with global sales exceeding $4 billion annually across multiple branded formulations. It is manufactured by several major pharmaceutical companies: Genotropin (Pfizer), Norditropin (Novo Nordisk), Humatrope (Eli Lilly), Omnitrope (Sandoz, a biosimilar), Saizen (EMD Serono), and Nutropin (Genentech). In 2020, the FDA approved Sogroya (somapacitan), a long-acting GH analog from Novo Nordisk that requires only once-weekly injection.

Beyond its approved medical uses, HGH is widely used off-label for anti-aging purposes and illicitly in bodybuilding. The landmark 1990 study by Rudman et al. in the New England Journal of Medicine -- which showed that six months of GH administration in elderly men increased lean body mass and decreased fat mass -- ignited the anti-aging growth hormone industry. However, subsequent systematic reviews have found that the risks of GH therapy in otherwise healthy elderly individuals likely outweigh the modest benefits (Liu et al., 2007). HGH is a Schedule III controlled substance in the United States, and its distribution for anti-aging or bodybuilding purposes is a federal crime under the 1990 Anabolic Steroids Control Act.

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

Growth hormone physiology involves a complex axis: the hypothalamus produces growth hormone-releasing hormone (GHRH, stimulatory) and somatostatin (inhibitory), which regulate pulsatile GH secretion from pituitary somatotrophs. A third input comes from ghrelin, which acts through the GHS-R1a receptor. When exogenous somatropin is injected, it bypasses this entire regulatory axis entirely -- the hormone enters circulation directly and acts on target tissues regardless of hypothalamic or pituitary signaling.

GH Receptor Binding and Signal Transduction

Somatropin binds to the growth hormone receptor (GHR), a transmembrane receptor belonging to the type I cytokine receptor superfamily. GHR exists as a preformed dimer on the cell surface. When one GH molecule binds to the two receptor subunits (through two distinct binding sites, Site 1 and Site 2), it induces a conformational change that activates the associated intracellular tyrosine kinase JAK2 (Janus Kinase 2). Activated JAK2 phosphorylates multiple downstream targets, primarily the transcription factor STAT5b, which translocates to the nucleus and activates gene transcription (Molitch et al., 2011).

Direct vs. Indirect Effects

Growth hormone exerts its biological effects through two distinct pathways -- a critical distinction for understanding both its therapeutic benefits and its side effects:

This dual action explains why GH has both anabolic/growth-promoting properties (IGF-1 mediated) and potentially diabetogenic properties (direct GH action). At physiologic replacement doses, the balance favors beneficial effects. At supraphysiologic doses used in bodybuilding, the direct insulin-antagonizing effects become clinically significant (Clemmons, 2012).

Exogenous HGH vs. Endogenous GH Secretion

A fundamental pharmacological distinction exists between injected HGH and natural pituitary GH secretion:

• Endogenous GH: Released in discrete pulses (6-12 per day, with the largest pulse during early slow-wave sleep). Between pulses, GH levels are nearly undetectable. This pulsatile pattern is biologically important -- certain GH effects (such as sexually dimorphic gene expression in the liver) are pattern-dependent.
• Exogenous HGH: A single daily subcutaneous injection produces a pharmacokinetic peak at 3-5 hours followed by a gradual decline. This creates a sustained, non-pulsatile GH elevation that does not replicate the natural secretory pattern. Continuous GH exposure differs biologically from pulsatile exposure.
• Negative feedback: Chronic exogenous HGH suppresses endogenous GH production via negative feedback (elevated IGF-1 inhibits GHRH release and stimulates somatostatin). This means the pituitary's own GH output diminishes during HGH therapy -- a key difference from GH secretagogues, which work through the pituitary and preserve its function.

The IGF-1 Axis

Approximately 75% of circulating IGF-1 is produced by the liver in response to GH stimulation. IGF-1 circulates bound to IGF-binding proteins (primarily IGFBP-3 and the acid-labile subunit), which extend its half-life to ~15-20 hours. Serum IGF-1 is used clinically as the primary biomarker of GH action and is the basis for dose titration in GH replacement therapy. Elevated IGF-1 above age-appropriate ranges indicates excessive GH effect and correlates with side effect risk (Hoffman et al., 2004).

Tissue-Specific Actions

• Adipose tissue: GH is the most potent endogenous lipolytic hormone. It activates hormone-sensitive lipase in adipocytes, promoting triglyceride breakdown and free fatty acid release. This effect is direct (not IGF-1 mediated) and is particularly pronounced in visceral adipose depots.
• Skeletal muscle: GH promotes amino acid uptake and protein synthesis, primarily through IGF-1. GH also enhances muscle fatty acid oxidation. However, the muscle hypertrophy effects of GH are modest compared to anabolic steroids.
• Bone: GH stimulates both osteoblast and osteoclast activity, with net anabolic effect on bone formation. IGF-1 mediates most of GH's effects on longitudinal bone growth (through growth plate chondrocyte proliferation in children).
• Connective tissue: GH and IGF-1 stimulate collagen synthesis in tendons, ligaments, cartilage, and skin.
• Kidney: GH promotes sodium reabsorption and water retention -- the basis for the edema and carpal tunnel syndrome seen as side effects.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

The Rudman Study (1990) -- The Paper That Launched an Industry

The single most influential study in the history of growth hormone therapy was published by Daniel Rudman and colleagues in the New England Journal of Medicine. In this small, non-randomized trial, 12 men aged 61-81 with low IGF-1 levels received recombinant HGH (0.03 mg/kg three times weekly) for six months. Results showed a 8.8% increase in lean body mass, a 14.4% decrease in adipose tissue mass, and a 1.6% increase in lumbar vertebral bone density. Rudman famously described these changes as equivalent to reversing 10-20 years of aging (Rudman et al., 1990).

This study was pivotal -- but deeply flawed by modern standards. It had no placebo control, no randomization, included only 12 subjects, and lasted only six months. Nevertheless, it spawned a multi-billion-dollar anti-aging GH industry. Rudman himself cautioned against extrapolating his findings to widespread clinical use, noting that long-term safety data was absent.

Systematic Review: GH in Healthy Elderly (Liu et al., 2007)

The definitive systematic review of GH therapy in healthy older adults was published in the Annals of Internal Medicine. Liu et al. analyzed 31 studies (involving 220 participants receiving GH) and found modest body composition effects: an average 2.1 kg increase in lean body mass and 2.1 kg decrease in fat mass. However, these changes were not associated with improvements in clinically meaningful outcomes -- no improvements in bone density, cholesterol levels, maximal oxygen consumption, or functional capacity were demonstrated. Meanwhile, side effects were common: edema (pooled odds ratio 8.32), arthralgias (5.73), carpal tunnel syndrome (3.35), and a trend toward increased diabetes risk (Liu et al., 2007).

The authors concluded: "Claims that growth hormone enhances physical performance are not supported by the scientific literature. Although growth hormone alters body composition, it does not appear to improve key outcomes that people care about."

GH Deficiency Treatment -- The Evidence Base

For patients with documented growth hormone deficiency (diagnosed by provocative testing), the evidence base is much stronger. Adults with GH deficiency demonstrate:

• Increased visceral adiposity and reduced lean body mass (Gibney et al., 1999)
• Reduced bone mineral density and increased fracture risk
• Adverse lipid profiles (increased LDL, decreased HDL)
• Impaired quality of life, including fatigue, reduced exercise capacity, and psychological distress
• Increased cardiovascular mortality in untreated GH deficiency

GH replacement in these patients reverses many of these abnormalities. The Endocrine Society clinical practice guideline recommends GH replacement for adults with confirmed GH deficiency, with dose titration based on clinical response and IGF-1 levels (Molitch et al., 2011).

Long-Term Cancer Risk (SAGhE / Swerdlow)

The long-term safety of childhood GH treatment has been extensively studied. The European SAGhE (Safety and Appropriateness of Growth Hormone Treatments in Europe) study reported a potential increase in mortality from bone tumors and cardiovascular events in adults who received GH during childhood, though results were inconsistent across countries and doses (Swerdlow et al., 2017).

Swerdlow et al. conducted one of the largest retrospective cohort studies, following over 23,000 patients treated with GH in childhood. They found no overall increase in cancer incidence but noted a modest increase in specific cancers (meningioma, bone tumors) in individuals treated at higher doses. The clinical significance of these findings remains debated, and confounding by the underlying conditions requiring GH treatment is difficult to exclude.

Growth Hormone and Aging (Bartke, 2019)

Paradoxically, while GH declines with age and GH replacement appears to improve body composition, animal research consistently shows that reduced GH/IGF-1 signaling is associated with increased lifespan. GH receptor knockout mice (Laron dwarf mice) live 40-50% longer than normal mice. This creates a fundamental paradox for anti-aging GH therapy: the very hormone being administered to "reverse aging" may actually accelerate aging at the cellular level (Bartke, 2019).

Safety of rhGH -- Comprehensive Review (Carel & Butler, 2010)

Carel and Butler published a comprehensive review of rhGH safety across all indications. Key findings included: the overall safety profile is favorable when used at replacement doses for approved indications; the risk of new-onset type 2 diabetes is modestly increased; intracranial hypertension is a rare but recognized adverse event in children; and surveillance for potential cancer risk should continue, particularly in patients treated during childhood (Carel & Butler, 2010).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA-Approved Indications

Off-Label Uses

HGH vs. GH Secretagogues: Key Differences

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

FDA-Approved Dosing (Adult GH Deficiency)

Dosing based on: Molitch et al., 2011 (Endocrine Society Clinical Practice Guideline)

Pediatric Dosing (by Indication)

Source: Molitch et al. (2011) — Endocrine Society Clinical Practice Guideline.

Long-Acting Formulation: Sogroya (Somapacitan)

Source: Sogroya (somapacitan) FDA label.

Off-Label / Bodybuilding Doses (for Reference Only)

Source: Hoffman et al. (2004) — Diagnosis and dose titration in adult GHD.

Monitoring Requirements

• IGF-1 levels: Primary dose-titration marker. Check at baseline and every 1-2 months during titration. Target: mid-normal range for age and sex.
• Fasting glucose / HbA1c: GH is diabetogenic. Monitor glucose homeostasis, especially in patients with risk factors.
• Thyroid function: GH can unmask central hypothyroidism or alter thyroid hormone metabolism. Check free T4 periodically.
• Cortisol: GH can unmask central adrenal insufficiency. Assess adrenal axis if clinically indicated.
• Lipid panel: Monitor for improvements (therapeutic) or deterioration.
• Body composition: DEXA scan for objective measurement of lean mass and fat mass changes.

Storage

• Unopened: Refrigerate at 2-8 degrees C (36-46 degrees F). Do not freeze. Protect from light.
• In-use: Most pen devices can be stored at room temperature (up to 25 degrees C) for 21-28 days (varies by brand). Consult specific product labeling.
• Reconstituted powder: Refrigerate and use within 14-28 days depending on formulation.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What the Evidence Shows

GH Replacement in Confirmed GH Deficiency

GH in Healthy Elderly Adults (Off-Label Anti-Aging)

Based on the systematic review by Liu et al. (2007), which pooled data from 31 studies:

The overall conclusion: in healthy elderly individuals without GH deficiency, the modest body composition benefits do not translate into meaningful functional improvements, while side effects are common and clinically significant (Liu et al., 2007).

Bodybuilding Context (Anecdotal / Observational)

No controlled clinical trials exist for bodybuilding-dose HGH. The following represents commonly reported observations from clinical practice and community reports:

• Fat loss: The most consistently reported benefit at supraphysiologic doses. Visible reduction in subcutaneous and visceral fat, particularly at doses of 4+ IU/day. Often described as a "leaner" look without significant weight change.
• Muscle growth: Modest compared to anabolic steroids. GH primarily supports lean mass preservation and hyperplasia (new muscle cells) rather than hypertrophy (larger cells). Most notable when combined with anabolic steroids.
• Recovery: Enhanced recovery from training and injuries is frequently reported. Connective tissue strengthening (tendons, ligaments) is considered a significant benefit.
• Skin and appearance: Improved skin quality, hair growth, and overall "look" -- often described as a more youthful appearance.
• Side effects at these doses: Carpal tunnel syndrome, severe water retention, insulin resistance (some users develop frank diabetes requiring insulin use), joint pain, potential organ enlargement (including heart), acromegalic features with prolonged use.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Common Side Effects (Dose-Dependent)

Metabolic Side Effects

Serious / Rare Side Effects

• Intracranial hypertension (pseudotumor cerebri): Rare but recognized, primarily in children. Presents with headache, visual changes, and papilledema. Requires immediate discontinuation and neurological evaluation.
• Slipped capital femoral epiphysis: In children -- hip/knee pain or limping during GH therapy requires urgent orthopedic evaluation.
• Acromegalic features (chronic supraphysiologic use): Prolonged GH excess causes brow ridge prominence, jaw growth (prognathism), hand and foot enlargement, coarsening of facial features, and organ enlargement (including cardiomegaly). These changes may be irreversible.
• Potential cancer risk: Elevated IGF-1 is associated with increased risk of colorectal, breast, and prostate cancers in epidemiological studies. Whether GH therapy-induced IGF-1 elevation translates to increased cancer risk remains under investigation. The Swerdlow et al. (2017) long-term surveillance study found no overall increase in cancer but noted modest increases in specific tumor types (Swerdlow et al., 2017).
• Sudden death in Prader-Willi syndrome: Reports of sudden death in severely obese PWS children on GH, potentially related to respiratory compromise. Requires sleep study and careful monitoring in this population.

Drug Interactions

• Insulin / oral hypoglycemics: GH antagonizes insulin action. Diabetic patients may require dose adjustment of glucose-lowering medications.
• Glucocorticoids: Corticosteroids blunt GH response and may reduce efficacy. GH can also unmask central adrenal insufficiency.
• Thyroid hormones: GH increases peripheral conversion of T4 to T3 and can unmask central hypothyroidism. Monitor thyroid function.
• Oral estrogen: Women on oral estrogen require higher GH doses due to first-pass hepatic effect reducing IGF-1 generation. Transdermal estrogen does not have this interaction.
• CYP450 substrates: GH may alter activity of CYP450 enzymes (particularly CYP3A4), potentially affecting metabolism of other drugs.

Contraindications

• Active malignancy: GH/IGF-1 can promote tumor growth. GH should not be initiated in patients with active cancer.
• Active proliferative or severe non-proliferative diabetic retinopathy
• Critical illness: GH is contraindicated in critically ill patients (acute respiratory failure, post-cardiac surgery, multiple trauma) -- a large RCT showed increased mortality in critically ill ICU patients receiving GH.
• Closed epiphyses + no GH deficiency: In children without a documented GH-responsive condition
• Active Prader-Willi syndrome with severe obesity, respiratory impairment, or sleep apnea
• Hypersensitivity to somatropin or any excipients

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Approval History

Approved Brands Comparison

WADA Prohibited Status

HGH is listed by the World Anti-Doping Agency (WADA) as a prohibited substance under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Two detection methods are used by WADA-accredited laboratories:

• Isoform test: Detects the ratio of 22-kDa (recombinant) to other GH isoforms. Recombinant HGH is pure 22-kDa, while endogenous GH includes multiple isoforms. Detection window: ~24-36 hours after injection.
• Biomarker test: Measures GH-dependent biomarkers (IGF-1, PIIINP [procollagen type III N-terminal peptide]). Longer detection window than isoform test but subject to inter-individual variability.

Standard Employer Drug Testing

Standard workplace drug panels (5-panel, 10-panel, 12-panel) do not test for HGH or IGF-1. These panels screen for common drugs of abuse. However, unlike research peptides, HGH is a Schedule III controlled substance -- possession without a valid prescription is a criminal offense regardless of whether drug testing detects it.

International Regulation

• United States: Schedule III controlled substance. FDA-approved for specific indications only. Federal criminal penalties for off-label distribution.
• United Kingdom: Prescription-only medicine (POM). Not a controlled substance but regulated under the Medicines Act. Importation for personal use is a legal gray area.
• Canada: Prescription drug. Not a controlled substance but regulated under the Food and Drugs Act.
• Australia: Schedule 4 (prescription only). Importation restricted under the Customs Act.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Branded Product Pricing (US, Retail)

Insurance Coverage

Insurance covers HGH only for FDA-approved indications with documented diagnosis. Coverage typically requires:

• Prior authorization: Nearly always required. Must document appropriate diagnostic testing (GH stimulation test, IGF-1 levels, MRI if indicated).
• Step therapy: Some plans require failure of other treatments first or use of biosimilar (Omnitrope) before covering originator brands.
• Specialist prescription: Most plans require prescriptions from an endocrinologist or pediatric endocrinologist.
• Periodic reauthorization: Ongoing coverage requires periodic documentation of continued medical necessity.
• Off-label use: Insurance will not cover HGH prescribed for anti-aging, bodybuilding, or any off-label indication. These costs are entirely out-of-pocket.

Cost Reduction Strategies

• Biosimilar (Omnitrope): 20-30% savings vs. originator brands with equivalent efficacy.
• Manufacturer patient assistance programs: Pfizer (Genotropin), Novo Nordisk (Norditropin), and others offer co-pay assistance for insured patients and free drug programs for qualifying uninsured patients.
• Specialty pharmacies: May negotiate lower prices than retail pharmacies.
• Pharmacy benefit managers: Some PBMs have preferred formulary status for specific brands at lower tier pricing.

Cost Comparison: HGH vs. Alternatives

Black Market / Underground Lab Pricing

Annual Cost Estimates

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Q: Is HGH the same as steroids?

Answer: No. HGH (somatropin) is a 191-amino acid protein hormone -- structurally and functionally distinct from anabolic-androgenic steroids (AAS), which are synthetic derivatives of testosterone. GH and steroids work through completely different receptors and signaling pathways. GH primarily affects fat metabolism, IGF-1 production, and tissue repair; steroids primarily drive muscle hypertrophy through androgen receptor activation. However, HGH is classified alongside anabolic steroids as a Schedule III controlled substance under the same legislation, and both are prohibited by WADA. In bodybuilding, they are often used together -- GH for fat loss and recovery, steroids for muscle growth.

Q: Will HGH make me taller as an adult?

Answer: No. Once growth plates (epiphyses) have fused -- which occurs during late adolescence -- HGH cannot increase height. GH increases linear growth only in children and adolescents with open growth plates. In adults, supraphysiologic GH causes acromegalic changes (thickening of bones in hands, feet, and jaw) but not increased height. The approved pediatric indications target children before growth plate closure (Molitch et al., 2011).

Q: Is HGH an effective anti-aging treatment?

Answer: This is the most debated question in endocrinology. The facts: GH production declines approximately 14% per decade after age 30 (the "somatopause"). GH replacement produces measurable body composition changes in older adults (+2 kg lean mass, -2 kg fat mass). However, the most rigorous systematic review of GH in healthy elderly found that these changes do not translate into improvements in strength, physical function, bone density, or cardiovascular endpoints -- while side effects (edema, joint pain, carpal tunnel, insulin resistance) are common. Furthermore, animal research consistently shows that reduced GH/IGF-1 signaling extends lifespan, creating a fundamental paradox (Liu et al., 2007; Bartke, 2019).

Q: What is the difference between HGH and GH secretagogues like ipamorelin or sermorelin?

Answer: This is a critical distinction. HGH is the actual growth hormone protein -- when injected, it enters the bloodstream directly, producing flat, sustained GH elevation that suppresses pituitary function. GH secretagogues (ipamorelin, sermorelin, CJC-1295, GHRP-2, GHRP-6) are small peptides that stimulate the pituitary to release its own GH in natural pulsatile bursts. Secretagogues preserve the pituitary's own function and produce GH within physiologic ranges (the pituitary has a ceiling on how much it will release). HGH has no ceiling -- the dose determines the GH level, which can reach supraphysiologic concentrations. Secretagogues are generally considered safer for this reason, but they are less potent and are not FDA-approved (except tesamorelin for HIV lipodystrophy). For confirmed GH deficiency where the pituitary is damaged, secretagogues will not work -- HGH replacement is required.

Q: Will HGH show up on a drug test at work?

Answer: Standard workplace drug panels (5-panel, 10-panel, 12-panel) do not test for HGH. These screens detect common drugs of abuse (amphetamines, cannabinoids, cocaine, opioids, etc.). HGH detection requires specialized tests (isoform ratio or biomarker panels) used exclusively by WADA-accredited anti-doping laboratories. However, unlike research peptides, HGH is a Schedule III controlled substance -- possession without a valid prescription is itself a criminal offense.

Q: Does HGH cause cancer?

Answer: This remains an open question. Elevated IGF-1 has been associated with increased risk of colorectal, breast, and prostate cancers in large epidemiological studies. However, the Swerdlow et al. (2017) cohort study of 23,000+ people treated with GH in childhood found no overall increase in cancer incidence, though modest increases in specific tumor types were noted. The Endocrine Society guidelines recommend that GH replacement should not be initiated in patients with active malignancy, and that patients with a history of cancer should be in remission and off anti-cancer therapy before starting GH. The theoretical risk of chronic IGF-1 elevation promoting occult cancers remains a concern, particularly at supraphysiologic doses (Swerdlow et al., 2017; Carel & Butler, 2010).

Q: Is generic / underground lab HGH safe?

Answer: HGH is one of the most counterfeited pharmaceuticals globally. Legitimate somatropin is expensive to produce (requires recombinant DNA technology and stringent quality control). Underground lab products have been found to contain sub-potent GH, no GH at all, contaminated preparations, or entirely different substances. Without pharmaceutical-grade manufacturing, storage, and quality testing, the risks include infection, immune reactions, and unpredictable dosing. Only FDA-approved somatropin products from licensed pharmacies provide reliable quality assurance.

Q: Can I boost my GH naturally instead of taking HGH?

Answer: Yes -- several lifestyle interventions have been shown to increase endogenous GH secretion: (1) quality sleep (the largest GH pulse occurs during slow-wave sleep); (2) high-intensity exercise (particularly resistance training and sprints); (3) intermittent fasting (GH increases significantly during fasting states); (4) maintaining low body fat (obesity suppresses GH secretion); (5) avoiding high-sugar meals before bedtime (insulin suppresses GH release). For individuals without pathologic GH deficiency, optimizing these natural GH amplifiers may achieve meaningful benefits without the risks, costs, and legal issues of exogenous HGH (Bartke, 2019).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• HGH (somatropin) is a 191-amino acid recombinant protein identical to endogenous human growth hormone. It is one of the few hormones that is FDA-approved for multiple medical indications, including pediatric and adult GH deficiency, Turner syndrome, Prader-Willi syndrome, chronic renal insufficiency, short bowel syndrome, and HIV-associated wasting.
• For confirmed GH deficiency, replacement therapy is well-supported by decades of clinical evidence. It improves body composition, bone density, lipid profiles, cardiovascular risk markers, and quality of life. Dose is titrated based on IGF-1 levels and clinical response, starting at 0.1-0.3 mg/day.
• For anti-aging use in otherwise healthy adults, the evidence is weak. The landmark Liu et al. (2007) systematic review found modest body composition changes (+2 kg lean mass, -2 kg fat mass) but no improvements in strength, function, bone density, or cardiovascular endpoints -- with high rates of side effects. Animal research paradoxically shows that reduced GH/IGF-1 signaling extends lifespan.
• HGH is a Schedule III controlled substance with unique legal restrictions. Federal law explicitly prohibits distribution for anti-aging or performance enhancement. Violations carry criminal penalties including imprisonment.
• Side effects are dose-dependent. At replacement doses: mild fluid retention, joint stiffness, occasional carpal tunnel symptoms. At supraphysiologic doses: significant edema, carpal tunnel, insulin resistance/diabetes, acromegalic features, potential organ enlargement, and theoretical cancer risk from elevated IGF-1.
• HGH differs fundamentally from GH secretagogues. Exogenous HGH produces flat, sustained GH levels and suppresses pituitary function. Secretagogues (ipamorelin, sermorelin, CJC-1295) stimulate pulsatile, physiologic GH release through the pituitary. Secretagogues are generally considered safer but less potent.
• Cost is very high: $700-$3,000+/month for pharmaceutical-grade products. Insurance covers only FDA-approved indications. Off-label and bodybuilding use is entirely out-of-pocket.
• Multiple branded products are available (Genotropin, Norditropin, Humatrope, Omnitrope, Saizen), with the biosimilar Omnitrope offering modest cost savings. Sogroya (somapacitan) provides a once-weekly alternative.
• Long-term cancer surveillance (Swerdlow et al., 2017) has not found an overall increase in cancer incidence but has noted modest increases in specific tumor types. The relationship between GH therapy-induced IGF-1 elevation and cancer risk remains an active area of investigation.

Questions to Ask Your Endocrinologist

• Do I have documented GH deficiency based on appropriate diagnostic testing (stimulation test, IGF-1 levels)?
• If my GH/IGF-1 is low-normal for my age, does that represent pathology or normal aging?
• What are the expected benefits and realistic timeline for my specific indication?
• What brand and delivery device do you recommend, and why?
• How will you monitor my response -- what IGF-1 range are you targeting?
• What are the specific risks given my medical history (diabetes risk, cancer history, cardiovascular status)?
• Would a GH secretagogue be a safer or more appropriate alternative for my goals?
• Could lifestyle interventions (sleep optimization, exercise, fasting, weight management) address my concerns without pharmacotherapy?
• What monitoring bloodwork and imaging should be done, and how frequently?
• What is the plan for ongoing treatment -- indefinite therapy or periodic reassessment?

Sources & Further Reading

Clinical Practice Guidelines

• Molitch ME, Clemmons DR, Malozowski S, et al. (2011) -- "Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline" -- Journal of Clinical Endocrinology & Metabolism, 96(6):1587-1609
• Hoffman AR, Strasburger CJ, Zagar A, et al. (2004) -- "Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy" -- Growth Hormone & IGF Research, 14(4):349-357

Landmark Studies

• Rudman D, Feller AG, Nagraj HS, et al. (1990) -- "Effects of human growth hormone in men over 60 years old" -- New England Journal of Medicine, 323(1):1-6
• Liu H, Bravata DM, Olkin I, et al. (2007) -- "Systematic review: the safety and efficacy of growth hormone in the healthy elderly" -- Annals of Internal Medicine, 146(2):104-115
• Gibney J, Wallace JD, Spinks T, et al. (1999) -- "The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients" -- Journal of Clinical Endocrinology & Metabolism, 84(8):2596-2602

Safety & Long-Term Risk

• Carel JC, Butler G (2010) -- "Safety of recombinant human growth hormone" -- Endocrine Reviews, 31(5):1-29
• Swerdlow AJ, Cooke R, Beckers D, et al. (2017) -- "Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study" -- Journal of Clinical Endocrinology & Metabolism, 102(5):1661-1672

Growth Hormone, Aging & IGF-1 Biology

• Bartke A (2019) -- "Growth hormone and aging: updated review" -- World Journal of Men's Health, 37(1):19-30
• Clemmons DR (2012) -- "Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes" -- Endocrinology and Metabolism Clinics of North America, 41(2):425-443

GH Deficiency -- Diagnosis & Body Composition

• Hoffman AR, et al. (2004) -- "Diagnosis and individualized dosing in adult GH deficiency" -- Growth Hormone & IGF Research
• Gibney J, et al. (1999) -- "Body composition and metabolic effects of 10-year GH replacement" -- JCEM

GH Secretagogues (Comparative)

• Raun K, Hansen BS, Johansen NL, et al. (1998) -- "Ipamorelin, the first selective growth hormone secretagogue" -- European Journal of Endocrinology, 139(5):552-561

Regulatory & Institutional Sources

• FDA: Human Growth Hormone (HGH) -- Drug Safety Information
• WADA: Prohibited List (current year)
• DEA: Controlled Substances Schedules
• 21 USC 333(e) -- Penalties for Distribution of HGH

Additional References

• Renehan AG, Zwahlen M, Minder C, et al. (2004) -- "Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis" -- The Lancet, 363(9418):1346-1353
• Thomas A, Thevis M, Delahaut P, et al. (2012) -- "Mass spectrometric detection of growth hormone-releasing peptides" -- Rapid Communications in Mass Spectrometry, 26(15):1679-1690

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.